Literature DB >> 12827362

Medical management of obesity.

J G Wechsler1, K Leopold.   

Abstract

BACKGROUND: Obesity is associated with elevated morbidity and death rates. The World Health Organization defines obesity as a chronic disease. The percentage of obese persons is increasing worldwide. Many different treatment modalities are available. Long-term success rates are not convincing. RESEARCH FOCUS: Overweight and obesity should be treated in an interdisciplinary and multimodal approach. The best results in loosing body weight, especially body fat use very low calorie diets followed by a fat-reduced, carbohydrate-rich diets. Weight-loss drugs should be used only in a weight-loss program including diet and physical activity. Surgical intervention is necessary in a small group of persons refractory to conservative obesity treatment.
CONCLUSIONS: New structured guidelines oriented and quality controlled programs for treatment of obese patients are necessary.

Entities:  

Mesh:

Year:  2003        PMID: 12827362     DOI: 10.1007/s00423-003-0377-3

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  13 in total

1.  Obesity: an innately incurable disease?

Authors:  B J Husemann
Journal:  Obes Surg       Date:  1999-06       Impact factor: 4.129

2.  Valvular heart disease associated with fenfluramine-phentermine.

Authors:  H M Connolly; J L Crary; M D McGoon; D D Hensrud; B S Edwards; W D Edwards; H V Schaff
Journal:  N Engl J Med       Date:  1997-08-28       Impact factor: 91.245

Review 3.  Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health.

Authors: 
Journal:  Obes Res       Date:  1998-09

4.  Long-term weight-loss maintenance: a meta-analysis of US studies.

Authors:  J W Anderson; E C Konz; R C Frederich; C L Wood
Journal:  Am J Clin Nutr       Date:  2001-11       Impact factor: 7.045

Review 5.  The role of low-fat diets and fat substitutes in body weight management: what have we learned from clinical studies?

Authors:  A Astrup; S Toubro; A Raben; A R Skov
Journal:  J Am Diet Assoc       Date:  1997-07

6.  Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance.

Authors:  W P James; A Astrup; N Finer; J Hilsted; P Kopelman; S Rössner; W H Saris; L F Van Gaal
Journal:  Lancet       Date:  2000 Dec 23-30       Impact factor: 79.321

7.  Pathologic Changes in the Stomach at the Site of Silicone Gastric Banding.

Authors: 
Journal:  Obes Surg       Date:  1991-03       Impact factor: 4.129

8.  Randomised comparison of diets for maintaining obese subjects' weight after major weight loss: ad lib, low fat, high carbohydrate diet v fixed energy intake.

Authors:  S Toubro; A Astrup
Journal:  BMJ       Date:  1997-01-04

Review 9.  Economic costs of obesity.

Authors:  G A Colditz
Journal:  Am J Clin Nutr       Date:  1992-02       Impact factor: 7.045

10.  Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study.

Authors:  H B Hubert; M Feinleib; P M McNamara; W P Castelli
Journal:  Circulation       Date:  1983-05       Impact factor: 29.690

View more
  3 in total

1.  [Significance of nutrition in obesity].

Authors:  J G Wechsler
Journal:  Internist (Berl)       Date:  2007-10       Impact factor: 0.743

2.  Obese African-American women's perspectives on weight loss and bariatric surgery.

Authors:  Cheryl Sterling Lynch; Judy C Chang; Angela F Ford; Said A Ibrahim
Journal:  J Gen Intern Med       Date:  2007-04-20       Impact factor: 5.128

3.  Obesity: prevalence, theories, medical consequences, management, and research directions.

Authors:  Colin Wilborn; Jacqueline Beckham; Bill Campbell; Travis Harvey; Melyn Galbreath; Paul La Bounty; Erika Nassar; Jennifer Wismann; Richard Kreider
Journal:  J Int Soc Sports Nutr       Date:  2005-12-09       Impact factor: 5.150

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.